Angelini Ventures deepens stake in CoMind with $60M funding

Angelini Ventures has doubled down on a UK neurotech start-up, joining a fresh $60 million financing that lifts the company’s total backing to $102.5 million. The capital injection, led by Plural and joined by a syndicate of existing and new investors, is earmarked to accelerate US regulatory work, expand clinical evidence and scale production of a bedside optical brain monitor.

The round was led by Plural, with participation from existing investors Angelini Ventures, Octopus Ventures and LocalGlobe, among others. To date, CoMind has raised a total of $102.5 million.

CoMind’s flagship device, CoMind One, uses low-power lasers and an external sensor to capture continuous, non-invasive measures of cerebral physiology. According to company briefings, the technology can assess cerebral blood flow, autoregulation and intracranial pressure from a single sensor — a combination not available from current bedside monitoring tools. The start-up says the platform also has scope to track oxygenation and metabolic signals, and to feed rich data streams into AI-driven decision-support tools.

The new funding will support a US regulatory pathway for the product, further clinical trials across intensive care and perioperative settings, and partnerships to industrialise manufacturing. Management highlighted the volume opportunity in neurocritical care: millions of patients worldwide undergo monitoring in intensive-care units, operating theatres and high-dependency wards each year, and clinicians currently rely on intermittent or invasive methods that are costly and hard to scale.

James Dacombe, CoMind’s founder and CEO, said the device aims to change how clinicians read the brain at the bedside, offering continuous physiological insight without surgical implantation. Elia Stupka, Managing Director of Angelini Ventures and board member since CoMind’s 2023 financing, framed the follow-on investment as a strategic fit for Angelini’s healthtech and drug-discovery portfolio, emphasising patient impact and system-level gains from more timely neurological data.

Market context strengthens the case for the technology. Demand for advanced neuro-monitoring solutions has been rising as hospitals focus on reducing avoidable neurological complications and shortening ICU stays. Industry forecasts point to steady growth in the brain-monitoring and neuromonitoring segments, where innovation is driven by non-invasive sensors, data analytics and tighter clinical evidence supporting earlier intervention.

For investors, CoMind sits at the intersection of medtech hardware and software-enabled diagnostics — an area attracting specialist venture and corporate capital given the prospect of high-margin devices coupled with subscription or analytics services. The ability to deliver continuous streams of validated physiological data could also open licensing pathways with device makers and electronic medical-record integrators.

Looking ahead, the success of the US regulatory filings and the outcomes of upcoming pivotal studies will be critical inflection points. If CoMind can demonstrate robust, reproducible correlations between its optical measurements and clinical endpoints, the technology could shift standard practice in neurocritical care and expand into perioperative monitoring and broader acute-care settings.